Oruka Therapeutics (ORKA) EPS (Weighted Average and Diluted) (2010 - 2024)
Oruka Therapeutics' quarterly EPS (Weighted Average and Diluted) came in at -$0.18 in Q2 2024, down 80.0% year-on-year from -$0.9 in Q3 2023, and down 28.57% quarter-over-quarter from -$0.14 in Q1 2024.
Oruka Therapeutics has reported EPS (Weighted Average and Diluted) for 7 years, with the latest figure at -$0.18 in Q2 2024.
- For the quarter ending Q2 2024, EPS (Weighted Average and Diluted) fell 80.0% year-over-year to -$0.18; the trailing twelve-month figure through Jun 2024 stood at -$0.5 (down 16.28% YoY), and the FY2023 full-year result was -$0.37, up 46.38% from the prior year.
- EPS (Weighted Average and Diluted) for Q2 2024 stood at -$0.18, down from -$0.14 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was -$0.08 in Q4 2022, with the low at -$0.4 in Q4 2021.
- Average EPS (Weighted Average and Diluted) over 4 years is -$0.19, with a median of -$0.16 recorded in 2022.
- Year-over-year, EPS (Weighted Average and Diluted) surged 80.0% in 2022 and sank 80.0% in 2024.
- Tracing ORKA's EPS (Weighted Average and Diluted) over 4 years: stood at -$0.4 in 2021, then surged by 80.0% to -$0.08 in 2022, then dropped by 0.0% to -$0.08 in 2023, then tumbled by 125.0% to -$0.18 in 2024.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.18 (Q2 2024), -$0.14 (Q1 2024), and -$0.08 (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Oruka Therapeutics | 3.04 Bn | 2.65 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -0.18 |
| Mar 31, 2024 | -0.14 |
| Dec 31, 2023 | -0.08 |
| Sep 30, 2023 | -0.10 |
| Jun 30, 2023 | -0.10 |
| Mar 31, 2023 | -0.09 |
| Dec 31, 2022 | -0.08 |
| Sep 30, 2022 | -0.16 |
| Jun 30, 2022 | -0.22 |
| Mar 31, 2022 | -0.23 |
| Dec 31, 2021 | -0.40 |
| Sep 30, 2021 | -0.33 |
| Jun 30, 2021 | -0.34 |
| Jun 30, 2012 | -0.09 |
| Jun 30, 2011 | 0.03 |
| Jun 30, 2010 | -0.26 |